Preclinical Alzheimer's Disease Clinical Trial
— VRCTOfficial title:
Concurrent Aerobic Exercise and Cognitive Training to Prevent Alzheimer's in At-risk Older Adults
NCT number | NCT02963415 |
Other study ID # | 1610M98324 |
Secondary ID | |
Status | Completed |
Phase | N/A |
First received | |
Last updated | |
Start date | March 1, 2019 |
Est. completion date | March 31, 2022 |
Verified date | June 2022 |
Source | University of Minnesota |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
The study will implement and test a unique Virtual Reality Cognitive Training (VRCT) combined with concurrent cycling on a recumbent stationary cycle, also known as exergame that seamlessly integrates specific cognitive tasks into a virtual environment and is synchronized with cycling to promote cognition.
Status | Completed |
Enrollment | 39 |
Est. completion date | March 31, 2022 |
Est. primary completion date | March 31, 2022 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 65 Years to 99 Years |
Eligibility | Inclusion Criteria: 1. Cognitive complaint (defined as answering yes to the question "Do you feel that your memory or thinking skills have gotten worse recently?) 2. Not engaging in aerobic exercise or cognitive training >2 days/week, 30 minutes a session in the past 3 months; 3. Age 65 years and older Exclusion Criteria: 1. Resting heart rate > 100 or < 50 beats/min; 2. Dementia (self-report, diagnosis, or scoring <18 on the modified Telephone Interview for Cognitive Status; 3. Neurological or major psychiatric disorder since memory problem; 4. Significant diseases, symptoms, or other factors that make exercise unsafe 5. Current enrollment in another intervention study |
Country | Name | City | State |
---|---|---|---|
United States | University of Minnesota | Minneapolis | Minnesota |
Lead Sponsor | Collaborator |
---|---|
University of Minnesota |
United States,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Feasibility of the exergame development | development of the exergame prototype by 3 months | Baseline to 3 months | |
Secondary | Cycling adherence rate | =70% subjects adhere to the cycling dose | 3-6 months | |
Secondary | VCRT adherence rate | =70% subjects adhere to the cognitive training dose | 3-6 months | |
Secondary | Usability and satisfaction with the exergame | Participants report acceptable usability and satisfaction with the exergame | 3-6 months |
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT06033066 -
Financial Incentives and Recruitment to the APT Webstudy
|
N/A | |
Enrolling by invitation |
NCT06416072 -
Alzheimer's Plasma Extension
|
||
Recruiting |
NCT04851496 -
Amyloid Prediction in Early Stage Alzheimer's Disease From Acoustic and Linguistic Patterns of Speech - PAST Extension
|
||
Terminated |
NCT04846426 -
Amyloid Prediction in Early Stage Alzheimer's Disease From Acoustic and Linguistic Patterns of Speech - FUTURE Extension
|
||
Completed |
NCT04828122 -
Amyloid Prediction in Early Stage Alzheimer's Disease From Acoustic and Linguistic Patterns of Speech
|
||
Completed |
NCT02045056 -
Modulation of Micro-RNA Pathways by Gemfibrozil in Predementia Alzheimer Disease
|
Early Phase 1 | |
Completed |
NCT03370744 -
Prediction of Cognitive Decline by Neuroimaging Techniques and the Application in Diagnosis and Treatment of Preclinical AD
|
||
Active, not recruiting |
NCT04004767 -
TRC-PAD Program: In-Clinic Trial-Ready Cohort
|
||
Recruiting |
NCT04468659 -
AHEAD 3-45 Study: A Study to Evaluate Efficacy and Safety of Treatment With Lecanemab in Participants With Preclinical Alzheimer's Disease and Elevated Amyloid and Also in Participants With Early Preclinical Alzheimer's Disease and Intermediate Amyloid
|
Phase 3 | |
Recruiting |
NCT04937959 -
Amyloid Prediction in Early Stage Alzheimer's Disease Through Speech Phenotyping - PAST Extension
|
||
Completed |
NCT04928976 -
Amyloid Prediction in Early Stage Alzheimer's Disease Through Speech Phenotyping
|
||
Terminated |
NCT04951284 -
Amyloid Prediction in Early Stage Alzheimer's Disease Through Speech Phenotyping - FUTURE Extension
|